Actively Recruiting
Evaluating the Effects of ARGX-121 Injections on Kidney Function and Proteinuria in Adults with IgA Nephropathy
Led by argenx · Updated on 2026-10-27
120
Participants Needed
11
Research Sites
16 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the effects of ARGX-121 on adults with Immunoglobulin A Nephropathy IgAN, a kidney condition. The study aims to assess changes in proteinuria, kidney function, drug distribution, elimination, and immune system response. Participants will continue their usual care for IgAN during the study unless advised otherwise by their doctor. This is a Phase 2 trial sponsored by argenx. Participants will receive subcutaneous injections of ARGX-121 during both a double-blinded period and an active treatment period, totaling up to 52 weeks of treatment. One group will receive placebo injections for the first 24 weeks before switching to ARGX-121 for 28 weeks. The study includes a double-blinded phase followed by an active drug phase and ends with a follow-up period, totaling about 72 weeks. During the study, participants will undergo assessments including urine protein-to-creatinine ratio measurements up to week 24, kidney function tests up to week 52, and monitoring of adverse events and biological markers up to week 68. Researchers will also track drug concentration and immune responses over time. Participants will have regular visits for injections and evaluations, with the study duration lasting around 72 weeks in total.
CONDITIONS
Brief Title
A Study to Evaluate the Effect of ARGX-121 on the Change in Proteinuria in Adult Participants With IgAN
Research Team
S
Sabine Coppieters, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here